We are live on ! Find out more
CLSD

Clearside Biomedical
CLSD

Delisted

CLSD was delisted on the 28th of November, 2025.

Back to rankings

51 hedge funds and large institutions have $23.8M invested in Clearside Biomedical in 2024 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 13 increasing their positions, 5 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 5

157% more capital invested

Capital invested by funds: $9.23M → $23.8M (+$14.5M)

42% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 12

11% more funds holding

Funds holding: 46 → 51 (+5)

0.54% more ownership

Funds ownership: 0.84% → 1.39% (+0.54%)

Holders
51
Holders Change
+5
Holders Change %
+10.87%
% of All Funds
0.73%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
13
Reduced
5
Closed
12
Calls
$104K
Puts
–
Net Calls
+$104K
Net Calls Change
+$19K

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$5.68M
2
RA
Rosalind Advisors
Ontario, Canada
+$3.73M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$452K
4
Jane Street
Jane Street
New York
+$254K
5
Millennium Management
Millennium Management
New York
+$249K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$195K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$129K
3
BCM
Bridgeway Capital Management
Texas
-$65.2K
4
N
Natixis
France
-$55.6K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$34.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$6.05M +$5.68M +263,733 New
RA
2
Rosalind Advisors
Ontario, Canada
$3.97M +$3.73M +172,840 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$3.81M +$452K +20,965 +14%
CG
4
Carmignac Gestion
France
$3.26M – – –
BlackRock
5
BlackRock
New York
$1.16M -$2.2K -102 -0.2%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$983K +$218K +10,101 +31%
Renaissance Technologies
7
Renaissance Technologies
New York
$837K +$233K +10,807 +42%
Millennium Management
8
Millennium Management
New York
$317K +$249K +11,552 +515%
State Street
9
State Street
Massachusetts
$296K – – –
Jane Street
10
Jane Street
New York
$270K +$254K +11,780 New
First Manhattan
11
First Manhattan
New York
$268K – – –
JJ
12
Johnson & Johnson
New Jersey
$260K – – –
CP
13
Castleview Partners
Texas
$248K +$233K +10,797 New
Morgan Stanley
14
Morgan Stanley
New York
$234K -$195K -9,055 -47%
Northern Trust
15
Northern Trust
Illinois
$204K +$60K +2,784 +46%
BCM
16
Bridgeway Capital Management
Texas
$199K -$65.2K -3,027 -26%
BWM
17
Brown Wealth Management
Illinois
$168K – – –
NFC
18
Northeast Financial Consultants
Connecticut
$142K – – –
Citadel Advisors
19
Citadel Advisors
Florida
$107K +$35K +1,622 +53%
Marshall Wace
20
Marshall Wace
United Kingdom
$105K +$98.4K +4,564 New
SF
21
Synovus Financial
Georgia
$81.2K – – –
CAPTRUST Financial Advisors
22
CAPTRUST Financial Advisors
North Carolina
$76.5K – – –
BCV
23
Banque Cantonale Vaudoise
Switzerland
$61K – – –
Stifel Financial
24
Stifel Financial
Missouri
$59.7K +$7.18K +333 +15%
IAIM
25
International Assets Investment Management
Florida
$56.9K +$51.7K +2,400 New
1
2 3

CLSD Hedge Fund Activity: Q1 2024 in Review

51 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q1 2024, worth a combined $23.8M — up 157% from $9.23M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new CLSD positions and 12 closed out — a net gain of 5 holders — while 13 added to existing stakes and 5 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $5.68M. The largest seller was Morgan Stanley, cutting an estimated $195K.

  • 51 institutional investors held Clearside Biomedical (CLSD) as of Q1 2024, up from 46 in Q4 2023.
  • Funds reported $23.8M of Clearside Biomedical stock for Q1 2024, up 157% quarter-over-quarter.
  • 17 funds opened new Clearside Biomedical positions in Q1 2024 and 12 closed out, a net change of +5 holders.
  • The largest Clearside Biomedical buyer in Q1 2024 was Armistice Capital, an estimated $5.68M added.
  • The largest Clearside Biomedical seller in Q1 2024 was Morgan Stanley, an estimated $195K sold.

Based on aggregated 13F filings for Q1 2024.